Who is sponsoring NCT00985855?

NCT00985855 is sponsored by Institut de Cancérologie de la Loire.

What condition does NCT00985855 study?

NCT00985855 studies Non-Small-Cell Lung Carcinoma.

What drugs are being tested in NCT00985855?

Interventions: cisplatin, vinorlebine, cetuximab, cisplatine, etoposide, cetuximab.

What is the status of NCT00985855?

NCT00985855 is currently COMPLETED.

Last reviewed 2017-09-13 · How we verify

Feasibility of Cetuximab (ERBITUX®) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study

NCT00985855 Phase 2 COMPLETED

Phase II, randomised, controlled, non comparative study with 2 parallel groups: * Arm A: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemotherapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy. * Arm B: patients will receive induction chemotherapy (cisplatin and docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.

Details

Lead sponsor	Institut de Cancérologie de la Loire
Phase	Phase 2
Status	COMPLETED
Enrolment	91
Start date	2009-09
Completion	2011-08

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

cisplatin, vinorlebine, cetuximab
cisplatine, etoposide, cetuximab

Primary outcomes

rate of patients presenting at least one toxicity grade≥3 (excepted hematological toxicity and nausea-vomiting) — End of concomitant treatment (Day 71)

Countries

France